The hospitalist perspective on treatment of community-acquired bacterial pneumonia

Postgraduate Medicine

Volumn 126, Issue 2, 2014, Pages 18-29

  Amin, Alpesh N ^a   Cerceo, Elizabeth A ^b   Deitelzweig, Steven B ^c   Pile, James C ^d   Rosenberg, David J ^e   Sherman, Bradley M ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Department of Surgery   (United States)

^c OCHSNER CLINIC FOUNDATION   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^f Northwell Health   (United States)

Author keywords

Antimicrobial therapy; Community acquired pneumonia; Hospital medicine; Hospitalist

Indexed keywords

BETA LACTAM; CEFTAROLINE; CEFTAROLINE FOSAMIL; CEPHALOSPORIN; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; TIGECYCLINE; ANTIINFECTIVE AGENT;

ARTICLE; CLINICAL TRIAL (TOPIC); COMMUNITY ACQUIRED PNEUMONIA; CURB 65; DRUG EFFICACY; DRUG SAFETY; HUMAN; LENGTH OF STAY; META ANALYSIS (TOPIC); MORTALITY; PATIENT CARE; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA SEVERITY INDEX; POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE ASSESSMENT; STREPTOCOCCUS PNEUMONIAE; THORAX RADIOGRAPHY; URINALYSIS; ANTIBIOTIC RESISTANCE; BACTERIAL PNEUMONIA; COMMUNITY ACQUIRED INFECTION; DIFFERENTIAL DIAGNOSIS; DRUG COMBINATION; HEALTH CARE QUALITY; HOSPITALIZATION; MEDICAL STAFF; MICROBIOLOGY; REVIEW; SEVERITY OF ILLNESS INDEX; STANDARD; STAPHYLOCOCCAL PNEUMONIA; STREPTOCOCCUS PNEUMONIA; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DIAGNOSIS, DIFFERENTIAL; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; HOSPITALISTS; HOSPITALIZATION; HUMANS; PNEUMONIA, BACTERIAL; PNEUMONIA, PNEUMOCOCCAL; PNEUMONIA, STAPHYLOCOCCAL; QUALITY INDICATORS, HEALTH CARE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84900551759     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2014.03.2737     Document Type: Article

References (90)

1. Bonafede MM, Suaya JA, Wilson KL, Mannino DM, Polsky D. Incidence and cost of CAP in a large working-age population. Am J Managed Care. 2012; 18(7): 380-387.
2. Hall MJ, DeFrances CJ, Williams SN, Golonsinskiy MS, Schwartzman A. National Hospital Discharge Survey: 2007 Summary. National Health Statistics Reports. 2010; 29: 1-24. Hyattsville, MD: Centers for Disease Control and Prevention.
3. Centers for Disease Control and Prevention. National Center for Health Statistics. Health, United States, 2012, with chartbook on trends in the health of Americans. http://www.cdc.gov/nchs/data/hus/hus06.pdf. Accessed June 26, 2013.
4. Jones RN, Sader HS, Mendes RE, Flamm RK. Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY antimicrobial surveillance program (1998-2011). Diagn Microbiol Infect Dis. 2013; 75(1): 107-109.
5. Farrell DJ, Castanheira M, Mendes RE, Sader HS, Jones RN. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE surveillance program (2008-2010). Clin Infect Dis. 2012; 55(suppl 3): S206-S214.
6. Mandell LA, Wunderink RG, Anzueto A, et al; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007; 44(suppl 2): S27-S72.
7. Lynch JP III, Zhanel GG. Streptococcus pneumoniae: does antimicrobial resistance matter? Semin Respir Crit Care Med. 2009; 30(2): 210-238.
8. Bartlett JG. Diagnostic tests for agents of community-acquired pneumonia. Clin Infect Dis. 2011; 52(Suppl 4): S296-S304.
9. File TM Jr, Low DE, Eckburg PE, et al; FOCUS 1 Investigators. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011; 66(suppl 3): iii19-iii32.
10. Moran GJ, Krishnadasan A, Gorwitz RJ, et al; EMERGEncy ID NET Study Group. Prevalence of methicillin-resistant Staphylococcus aureus as an etiology of community-acquired pneumonia. Clin Infect Dis. 2012; 54(8): 1126-1133.
11. Metersky ML, Masterton RG, Lode H, File TM Jr, Babinchak T. Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza. Int J Infect Dis. 2012; 16(5): e321-e331.
12. Wunderink RG. How important is methicillin-resistant Staphylococcus aureus as a cause of community-acquired pneumonia and what is best antimicrobial therapy? Infect Dis Clin North Am. 2013; 27(1): 177-188.
13. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of cuture-positive pneumonia. Chest. 2005; 128(6): 3854-3862.
14. Chalmers JD, Taylor JK, Singanayagam A, et al. Epidemiology, antibiotic therapy, and clinical outcomes in health care-associated pneumonia: a UK cohort study. Clin Infect Dis. 2011; 53(2): 107-113.
15. Pavia AT. What is the role of respiratory viruses in community-acquired pneumonia?: What is the best therapy for influenza and other viral causes of community-acquired pneumonia? Infect Dis Clin North Am. 2013; 27(1): 157-175.
16. Cillóniz C, Ewig S, Polverino E, et al. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax. 2011; 66(4): 340-346.
17. Hash RB, Stephens JL, Laurens MB, Vogel RL. The relationship between volume status, hydration, and radiographic findings in the diagnosis of community-acquired pneumonia. J Fam Pract. 2000; 49(9): 833-837.
18. Ressig A, Gramegna A, Aliberti S. The role of lung ultrasound in the diagnosis and follow-up of community-acquired pneumonia. Eur J Intern Med. 2012; 23(5): 391-397.
19. Ressig A, Copetti R, Mathis G, et al. Lung ultrasound in the diagnosis and follow-up of community-acquired pneumonia: a prospective, multicenter, diagnostic accuracy study. Chest. 2012; 142(4): 965-972.
20. Alves dos Santos JW, Torres A, Michel GT, et al. Non-infectious and unusual infectious mimics of community-acquired pneumonia. Respir Med. 2004; 98(6): 488-494.
21. Rome L, Murali G, Lippmann M. Nonresolving pneumonia and mimics of pneumonia. Med Clin North Am. 2001; 85(6): 1511-1530.
22. Tang KL, Eurich DT, Minhas-Sandhu JK, Marrie TJ, Majumdar SR. Incidence, correlates, and chest radiographic yield of new lung cancer diagnosis in 3398 patients with pneumonia. Arch Intern Med. 2011; 171(13): 1193-1198.
23. File TM Jr. New diagnostic tests for pneumonia: what is their role in clinical practice? Clin Chest Med. 2011; 32(3): 417-430.
24. BioFire Diagnostics, Inc. FilmArray Respiratory Panel. http:// www.biofiredx.com/pdfs/FilmArray/InfoSheet, %20FilmArray%20 Respiratory%20Panel-0229.pdf. Accessed September 18, 2013.
25. illumigene [package insert]. Cincinnati, OH: Meridian Bioscience, Inc.; 2013.
26. Upadhyay S, Niederman MS. Biomarkers: what is their benefit in the identification of infection, severity assessment, and management of community-acquired pneumonia? Infect Dis Clin North Am. 2013; 27(1): 19-31.
27. Schuetz P, Christ-Crain M, Thomann R, et al; ProHOSP Study Group. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009; 302(10): 1059-1066.
28. van Vugt SF, Broekhuizen BDL, Lammens C, et al; Grace Consortium. Use of serum C reactive protein and procalcitonin concentrations in addition to symptoms and signs to predict pneumonia in patients presenting to primary care with acute cough: diagnostic study. BMJ. 2013; 346: f2450.
29. Sinclair A, Xie X, Dendukuri N. The clinical effectiveness and cost of a pneumococcal urine antigen immunochromatographic test (BinaxNOW Streptococcus pneumoniae) in the diagnosis of community acquired Streptococcus pneumoniae pneumonia in patients admitted to hospital. Montreal (Canada): Technology Assessment Unit (TAU) of the McGill University Health Centre (MUHC); 2012. Report no. 57. 58 p. https:// secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/muhc_tau_2011_57_ binaxnow.pdf. Accessed October 28, 2013.
30. Marti C, Garin N, Grosgurin O, et al. Prediction of severe communityacquired pneumonia: a systematic review and meta-analysis. Crit Care. 2012; 16(4): R141.
31. Pereira JM, Paiva JA, Rello J. Assessing severity of patients with community-acquired pneumonia. Semin Respir Crit Care Med. 2012; 33(3): 272-283.
32. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community acquired pneumonia. N Engl J Med. 1997; 336(4): 243-250.
33. Chalmers JD, Singanayagam A, Akram A, et al. Severity assessment tools for predicting mortality in hospitalized patients with community-acquired pneumonia. Systemic review and meta-analysis. Thorax. 2010; 65(10): 878-883.
34. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003; 58(5): 377-382.
35. Choudhury G, Chalmers JD, Mandal P, et al. Physician judgement is a crucial adjunct to pneumonia severity scores in low-risk patients. Eur Respir J. 2011; 38(3): 643-648.
36. Brown RB, Iannini P, Gross P, Kunkel M. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. Chest. 2003; 123(5): 1503-1511.
37. Cai Y, Wang R, Liang B, Bai N, Liu Y. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother. 2011; 55(3): 1162-1172.
38. Tanaseanu C, Bergallo C, Tegalia O, et al; 308 Study Group; 313 Study Group. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis. 2008; 61(3): 329-338.
39. US Food and Drug Administration. Drug Safety Communication. Tygacil (tigecycline): Label Change-Increased Mortality Risk. September 2010. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm224626.htm. Accessed September 23, 2013.
40. Tygacil [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc.; 2013.
41. US Food and Drug Administration. FDA Drug Safety Communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new Boxed Warning. September 2013. http://www.fda.gov/Drugs/DrugSafety/ucm369580.htm. Accessed September 30, 2013.
42. Moisan H, Pruneau M, Malouin F. Binding of ceftaroline to penicillinbinding proteins of Staphylococcus aureus and Streptococcus pneumoniae. J Antimicrob Chemother. 2010; 65(4): 713-716.
43. Kosowska-Shick K, McGhee PL, Appelbaum PC. Affinity of ceftaroline and other β-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother. 2010; 54(5): 1670-1677.
44. Teflaro [prescribing information]. New York, NY: Forest Laboratories, Inc.; 2013.
45. Low DE, File TM Jr, Eckburg PB, et al; FOCUS 2 investigators. FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of efficacy and safety of ceftaroline fosamil versus ceftriaxone in communityacquired pneumonia. J Antimicrob Chemother. 2011; 66(suppl 3): iii33-iii44.
46. File TM Jr, Low DE, Eckburg PE, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, double-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis. 2010; 51(12): 1395-1405.
47. US FDA Briefing Document for Anti-Infective Drugs Advisory Committee Meeting. Ceftaroline fosamil for the treatment of communityacquired bacterial pneumonia and complicated skin and skin structure infections. September 7, 2010. http://www.fda.gov/downloads/advisorycommittees/ committeesmeetingmaterials/drugs/anti-infectivedrugsadvisorycommittee/ ucm224656.pdf. Accessed September 23, 2013.
48. Eckburg PB, Friedland HD, Llorens L, et al. Day 4 clinical response of ceftaroline fosamil versus ceftriaxone for community-acquired bacterial pneumonia. Infect Dis Clin Pract. 2012; 20(4): 254-260.
49. Rank DR, Friedland HD, Laudano JB. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother. 2011; 66(suppl 3): iii53-iii59.
50. Halm EA, Fine MJ, Kapoor WN, Singer DE, Marrie TJ, Siu AL. Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. Arch Intern Med. 2002; 162(11): 1278-1284.
51. Nathan RV, Rhew DC, Murray C, Bratzler DW, Houck PM, Weingarten SR. In-hospital observation after antibiotic switch in pneumonia: a national evaluation. Am J Med. 2006; 119(6): 512.e1-512.e7.
52. File TM Jr, Niederman MS. Antimicrobial therapy of community-acquired pneumonia. Infect Dis Clin North Am. 2004; 18: 993-1016.
53. Li JZ, Winston LG, Moore DH, Bent S. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med. 2007; 120(9): 783-790.
54. Shorr AF, Zadeikis N, Xiang JX, Tennenberg AM, Wes Ely E. A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged. or = 65 years with community-acquired pneumonia. Clin Ther. 2005; 27(8): 1251-1259.
55. el Moussaoui R, de Borgie CA, van den Broek P, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ. 2006; 332(7554): 1355.
56. Oster G, Berger A, Edelsberg J, Weber DJ. Initial treatment failure in non-ICU community-acquired pneumonia: risk factors and association with length of stay, total hospital charges, and mortality. J Med Econ. 2013; 16(6): 809-819.
57. Kollef MH. Broad-spectrum antimicrobials and the treatment of serious bacterial infections: getting it right up front. Clin Infect Dis. 2008; 47(suppl 1): S3-S13.
58. Avdic E, Cushinotto LA, Hughes AH, et al. Impact of an antimicrobial stewardship intervention on shortening the duration of therapy for community-acquired pneumonia. Clin Infect Dis. 2012; 54(11): 1581-1587.
59. Centers for Disease Control. Institute for Healthcare Improvement. Antibiotic Stewardship Driver Diagram and Change Package. July 2012. http://www.cdc.gov/getsmart/healthcare/pdfs/Antibiotic_Stewardship_ Change_Package_10_30_12.pdf. Accessed July 3, 2013.
60. Rohde JM, Jacobsen D, Rosenberg DJ. Role of the hospitalist in antimicrobial stewardship: a review of work completed and description of a multisite collaborative. Clin Ther. 2013; 35(6): 751-757.
61. Srinivasan A. Three Steps to Antibiotic Stewardship. CDC Expert Commentary. Published 15 Nov 2010. http://www.medscape.com/ viewarticle/731784. Accessed July 3, 2013.
62. Murray C, Shaw A, Lloyd M, et al. A multidisciplinary intervention to reduce antibiotic duration in lower respiratory tract infections. J Antimicrob Chemother. 2014; 69(2)515-518.
63. Menéndez R, Torres A, Zalacaín R, et al; Neumofail Group. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax. 2004; 59(11): 960-965.
64. Rosón B, Carratalà J, Fernández-Sabé N, Tubau F, Manresa F, Gudiol F. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med. 2004; 164(5): 502-508.
65. Fein AM. Pneumonia in the elderly: overview of diagnostic and therapeutic approaches. Clin Infect Dis. 1999; 28(4): 726-729.
66. Macfarlane JT, Miller AC, Roderick Smith WH, Morris AH, Rose DH. Comparative radiographic features of community acquired Legionnaires' disease, pneumococcal pneumonia, Mycoplasma pneumoniae, and psittacosis. Thorax. 1984; 39: 28-33.
67. Sialer S, Liapikou A, Torres A. What is the best approach to the nonresponding patient with community-acquired pneumonia? Infect Dis Clin North Am. 2013; 27(1): 189-203.
68. Ewig S, de Roux A, Bauer T, et al. Validation of predictive rules and indices of severity for community acquired pneumonia. Thorax. 2004; 59(5): 421-427.
69. The Joint Commission. Pneumonia National Hospital Inpatient Quality Measures (table). November 2, 2011. http://www.jointcommission.org/ assets/1/6/Pneumonia.pdf. Accessed July 18, 2013.
70. Metersky ML, Ma A, Bratzler DW, Houck PM. Predicting bacteremia in patients with community-acquired pneumonia. Am J Respir Crit Care Med. 2004; 169(3): 342-347.
71. Metersky ML. Should management of pneumonia be an indicator of quality of care? Clin Chest Med. 2011; 32(3): 575-589.
72. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med. 2001; 161(15): 1837-1842.
73. Baddour LM, Yu VL, Klugman KP, et al; International Pneumococcal Study Group. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med. 2004; 170(4): 440-444.
74. Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med. 1999; 159(21): 2562-2572.
75. Martinez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a β-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis. 2003; 36(4): 389-395.
76. Bratzler DW, Nsa W, Houck PM. Performance measures for pneumonia: are they valuable and are process measures adequate? Curr Opin Infect Dis. 2007; 20(2): 182-189.
77. Johnstone J, Mandell L. Guidelines and quality measures: do they improve outcomes of patients with community-acquired pneumonia? Infect Dis Clin North Am. 2013; 27(1): 71-86.
78. Jha A, Joynt K, Orav J, Epstein AM. The long-term effect of premier pay for performance on patient outcomes. N Engl J Med. 2012; 366(17): 1606-1615.
79. Arnold FW, Ramirez JA, McDonald C, Xia EL. Hospitalization for community-acquired pneumonia: the pneumonia severity index vs clinical judgment. Chest. 2003; 124(1): 121-124.
80. Carratalà J, Garcia-Vidal C, Ortega L, et al. Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial. Arch Intern Med. 2012; 172(12): 922-928.
81. Fisher SR, Kuo Y, Graham JE, Ottenbacher KJ, Ostir GV. Early ambulation and length of stay in older adults hospitalized with acute illness. Arch Intern Med. 2010; 170(21): 1942-1943.
82. Scheurer DB, Miller JG, Blair DI, Pride PJ, Walker GM, Cawley PJ. Hospitalists and improved cost savings in patients with bacterial pneumonia at a state level. South Med J. 2005; 98(6): 607-610.
83. Bell CM, Schnipper JL, Auerback AD, et al. Association of communication between hospital-based physicians and primary care providers with patient outcomes. J Gen Intern Med. 2008; 24(3): 381-386.
84. Lin CY, Barnato AE, Degenholtz HB. Physician follow-up visits after acute care hospitalization for elderly Medicare beneficiaries discharged to noninstitutional settings. J Am Geriatr Soc. 2011; 59(10): 1947-1954.
85. The Joint Commission. Centers for Medicare and Medicaid Services. Specifications Manual for National Hospital Inpatient Quality Measures. Discharges 01-01-13 (1Q13) through 12-31-13 (4Q13). CMS Readmission Measures (READM-30-PN). Version 4.2: 10-34-10-39. http://www.jointcommission.org/assets/1/6/NHQM_Release_Notes_ v4_2b_1.1.2013.pdf. Accessed July 1, 2013.
86. Capelastegui A, España Yandiola PP, Quintana JM, et al. Predictors of short-term rehospitalization following discharge of patients hospitalized with community-acquired pneumonia. Chest. 2009; 136(4): 1079-1085.
87. Jasti H, Mortensen EM, Obrosky DS, Kapoor WN, Fine MJ. Causes and risk factors for rehospitalization of patients hospitalized with community- acquired pneumonia. Clin Infect Dis. 2008; 46(4): 550-556.
88. Dharmarajan K, Hsieh AF, Lin Z, et al. Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA. 2013; 309(4): 355-363.
89. Shorr AF, Zilberberg MD, Reichley R, et al. Readmission following hospitalization for pneumonia: the impact of pneumonia type and it implication for hospitals. Clin Infect Dis. 2013; 57(3): 362-367.
90. Donzé J, Aujesky D, Williams D, Schnipper JL. Potentially avoidable 30-day hospital readmissions in medical patients. JAMA Intern Med. 2013; 173(8): 632-638.